Trial Profile
Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Oct 2020
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Dacarbazine; Doxorubicin
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 26 Jul 2020 Status changed from active, no longer recruiting to completed.
- 26 Jul 2019 Planned End Date changed from 1 Dec 2022 to 1 Jul 2020.
- 26 Jul 2019 Status changed from completed to active, no longer recruiting.